» Articles » PMID: 28451753

Histologic Subtype Needs to Be Considered After Partial Nephrectomy in Patients with Pathologic T1a Renal Cell Carcinoma: Papillary Vs. Clear Cell Renal Cell Carcinoma

Overview
Specialty Oncology
Date 2017 Apr 29
PMID 28451753
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We compared the oncological outcomes of papillary renal cell carcinoma (pRCC) with clear cell renal cell carcinoma (ccRCC) after partial nephrectomy (PN) in patients with pathologic T1a RCC.

Methods: After excluding patients with synchronous multiple renal tumors, familial RCC, and pathologic stage T1b or above, 759 patients with ccRCC and 84 patients with pRCC were included. We assessed the impact of histologic subtypes on oncologic outcomes after PN in patients with pathologic T1a RCC (median follow-up duration, 67 months).

Results: There was no difference in patient and tumor characteristics between the 2 groups, except Fuhrman grade (p = 0.006). Kaplan-Meier analysis identified 5-year recurrence-free survival of 98.7 and 95.6% in patients with ccRCC and pRCC, respectively. However, 10-year recurrence-free survival in patients with ccRCC and pRCC was 96.1 and 73.0%, respectively (p < 0.001). Recurrence ≥5 years post surgery was more common in patients with pRCC compared with those with ccRCC (0.3 vs. 4.8%; p < 0.001). In multivariate analysis, pRCC [hazard ratio (HR) 5.309; p = 0.001] was a significant risk factor for recurrence after PN in patients with pathologic T1a RCC, in addition to larger tumor size (HR 1.861; p = 0.038) and Fuhrman grade ≥3 (HR 5.176; p = 0.003).

Conclusions: In patients with pathologic T1a RCC, recurrence after PN occurred more commonly in pRCC compared with ccRCC. As over half of the recurrence cases in patients with pRCC occurred ≥5 years post surgery, a longer follow-up time is required, even for those with pathologic stage T1a disease.

Citing Articles

Development and validation of a prognostic model based on m6A-related lncRNAs to predict prognosis for papillary renal cell cancer patients.

Zhang X, Hu J, Zheng H, Ren J, Mu S, Chen Y Sci Rep. 2024; 14(1):31460.

PMID: 39732963 PMC: 11682231. DOI: 10.1038/s41598-024-83263-0.


Localized abdominal wall metastasis of papillary renal cell carcinoma: a case report.

Nahal C, Wunker C, Keller J Front Surg. 2024; 11:1413188.

PMID: 39583551 PMC: 11582055. DOI: 10.3389/fsurg.2024.1413188.


Novel molecular classification and prognosis of papillary renal cell carcinoma based on a large-scale CRISPR-Cas9 screening and machine learning.

Liu C, Yuan Z, Zhang X, Chang J, Yang Y, Sun S Heliyon. 2024; 10(1):e23184.

PMID: 38163209 PMC: 10754875. DOI: 10.1016/j.heliyon.2023.e23184.


Impact of Renal Cell Carcinoma Histological Variants on Recurrence After Partial Nephrectomy: A Multi-Institutional, Prospective Study (UROCCR Study 82).

Tabourin T, Pinar U, Parra J, Vaessen C, Bensalah C, Audenet F Ann Surg Oncol. 2022; 29(11):7218-7228.

PMID: 35780452 DOI: 10.1245/s10434-022-12052-8.


Giant Polycystic Papillary Renal Cell Carcinoma: A Case Report and Literature Review.

Huang Z, Wang H, Ji Z Front Oncol. 2022; 12:876217.

PMID: 35646650 PMC: 9134105. DOI: 10.3389/fonc.2022.876217.


References
1.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M . EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015; 67(5):913-24. DOI: 10.1016/j.eururo.2015.01.005. View

2.
Lee C, You D, Yoo S, Song C, Hong B, Hong J . Oncological outcomes of patients with incidental pathological T3a stage small renal cell carcinoma after partial nephrectomy. J Cancer Res Clin Oncol. 2016; 142(7):1651-7. DOI: 10.1007/s00432-016-2172-x. View

3.
Siegel C . Re: Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. J Urol. 2012; 188(1):66-7. DOI: 10.1016/j.juro.2012.03.063. View

4.
Fu W, Huang G, Moloo Z, Girgis S, Patel V, Low G . Multimodality Imaging Characteristics of the Common Renal Cell Carcinoma Subtypes: An Analysis of 544 Pathologically Proven Tumors. J Clin Imaging Sci. 2017; 6:50. PMC: 5209859. DOI: 10.4103/2156-7514.197026. View

5.
Leibovich B, Lohse C, Crispen P, Boorjian S, Thompson R, Blute M . Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010; 183(4):1309-15. DOI: 10.1016/j.juro.2009.12.035. View